![](https://storage.googleapis.com/iex/api/logos/CLDX.png)
Industry
Biotechnology
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 5:45 pm
Portfolio Pulse from Benzinga Insights
August 12, 2024 | 12:01 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:08 pm
Portfolio Pulse from Avi Kapoor
July 30, 2024 | 5:53 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 1:58 pm
Portfolio Pulse from Avi Kapoor
July 30, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:43 am
Portfolio Pulse from Avi Kapoor
July 30, 2024 | 9:50 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.